Enoblituzumab, previously known as TJ-271 or MGA271, represents the innovative therapeutic specific to CD33, the marker found predominantly on cancer tissues. This agent functions as a bispecific construct, https://lewisiszb793682.blognody.com/50554165/enoblituzumab-a-deep-dive-into-tj-271-and-mga271